Cohen's S.A.C. Capital Discloses 6.3% Stake in Barrier Therapeutics (BTRX)
More News related to BTRX
- Agile Therapeutics Appoints Industry Expert, Al Altomari, as Chairman of Its Board of Directors
- FTN Midwest Downgrades Barrier Therapeutics (BTRX) to Neutral
- Stiefel Laboratories, Inc. Successfully Completes Tender Offer for Shares of Barrier Therapeutics, Inc.
- Stiefel Laboratories, Inc. Successfully Completes Tender Offer for Shares of Barrier Therapeutics, Inc.
- Stiefel Laboratories Announces Expiration of Waiting Period to Acquire Barrier (BTRX)
In a 13G filing after the close Friday on Barrier Therapeutics Inc. (Nasdaq: BTRX), Steven Cohen's S.A.C. Capital disclosed a 6.3% stake (2,214,382 shares) in the company. At the quarter ended March 31, 2008, S.A.C. did not show a stake in Barrier.
Barrier Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of pharmaceutical products in the field of dermatology in the United States.
Related Categories
13GsStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
